Trademark: 87710776
Word
DURESTA
Status
Dead
Status Code
605
Status Date
Thursday, December 17, 2020
Serial Number
87710776
Mark Type
4000
Filing Date
Wednesday, December 6, 2017
Published for Opposition
Tuesday, April 17, 2018
Abandoned Date
Wednesday, December 16, 2020

Trademark Owner History
Allergan Sales, LLC - Owner At Publication

Classifications
5 Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Trademark Events
Dec 17, 2020
Abandonment Notice E-Mailed - After Publication
Dec 17, 2020
Abandonment - After Publication
Dec 16, 2020
Teas Express Abandonment Received
Dec 4, 2020
Teas Extension Received
May 30, 2020
Notice Of Approval Of Extension Request E-Mailed
May 28, 2020
Extension 4 Granted
May 28, 2020
Extension 4 Filed
May 28, 2020
Teas Extension Received
Dec 10, 2019
Notice Of Approval Of Extension Request E-Mailed
Dec 6, 2019
Extension 3 Granted
Dec 6, 2019
Extension 3 Filed
Dec 6, 2019
Teas Extension Received
Mar 19, 2019
Notice Of Approval Of Extension Request E-Mailed
Mar 15, 2019
Extension 2 Granted
Mar 15, 2019
Extension 2 Filed
Mar 15, 2019
Teas Extension Received
Nov 3, 2018
Notice Of Approval Of Extension Request E-Mailed
Nov 1, 2018
Extension 1 Granted
Nov 1, 2018
Extension 1 Filed
Nov 1, 2018
Teas Extension Received
Jun 12, 2018
Noa E-Mailed - Sou Required From Applicant
Apr 17, 2018
Official Gazette Publication Confirmation E-Mailed
Apr 17, 2018
Published For Opposition
Mar 28, 2018
Notification Of Notice Of Publication E-Mailed
Mar 14, 2018
Approved For Pub - Principal Register
Mar 13, 2018
Assigned To Examiner
Dec 17, 2017
New Application Office Supplied Data Entered In Tram
Dec 9, 2017
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24